WuXi Biologics enters first commercial manufacturing agreement

By Ben Hargreaves contact

- Last updated on GMT

(Image: Getty/Metamorworks)
(Image: Getty/Metamorworks)

Related tags: Wuxi biologics, Amicus Therapeutics, Pompe disease, China

WuXi Biologics agrees five-year deal with Amicus for the commercial production of a biologic for the treatment of Pompe disease.

Amicus Therapeutics and WuXi Biologics have been partnered on progressing ATB200, one part of an investigational Pompe disease therapy, since 2012.

The agreement has reached the commercial stage, in which WuXi will be the drug substance and drug product supplier. WuXi stated that both would be manufactured at two sites across its commercial supply network, which has a presence in Europe, China and the US.

The initial contract covers a five-year term, which will be automatically extended every two years unless one of the partners cancels.

ATB200 is the focus of the agreement and is one part of investigational therapy AT-GAA – comprised of a recombinant human acid alpha-glucosidase enzyme, an ‘optimised’ carbohydrate structure (ATB200) and a small molecule pharmacological chaperone (AT2221).

Bradley Campbell, COO of Amicus said in a statement, "Over the past five years we have successfully collaborated in the scale-up of our Pompe biologic from research to commercial scale while maintaining all key quality attributes.”

The investigational therapy is currently in Phase III trials, with an estimated study completion date of January 2021.

"We are excited about this exclusive commercial manufacturing partnership with Amicus, our first since the inception of the company,”​ said Chris Chen, CEO of WuXi Biologics.

Chen further explained that this partnership deal marked the company’s ability to produce ‘difficult biologics’, citing the structure of the drug candidate as a challenge in the development process.

WuXi Biologics has been on an investment drive to improve its capabilities, in recent years; beyond expanding its European presence and building out its capabilities​ in China where it is headquartered.

Related news

Show more

Related products

show more

dPCR Case Study

dPCR Case Study

CellCarta | 08-Aug-2022 | Case Study

Streamline your adoptive cell therapy program with digital PCR. Our team has a unique expertise in digital and quantitative PCR to support you in ensuring...

The Reagents Behind Much of Molecular Biology

The Reagents Behind Much of Molecular Biology

Thermo Fisher Scientific | 25-Jul-2022 | Case Study

The ability to amplify, modify and fabricate DNA is fundamental to modern molecular biology. Why do so many researchers take their constituent parts for...

Microsampling in Early Phase Drug Development

Microsampling in Early Phase Drug Development

Altasciences | 10-May-2022 | Technical / White Paper

Microsampling significantly lessens the volume of blood and plasma/serum that is collected and analyzed to determine circulating concentrations of therapeutic...

Seasonal Vaccine Manufacturing

Seasonal Vaccine Manufacturing

Baxter BioPharma Solutions | 16-Feb-2022 | Technical / White Paper

The production of seasonal vaccines, such as those for influenza, presents unique challenges to manufacturers due to the necessary time constraints resulting...

Related suppliers

Follow us


View more